{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-034277","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2024-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.630415+00:00","generated_at":"2026-05-31T13:27:56.113417+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Twist Bioscience Q3 FY2024 revenue $81.5M (+28% YoY); raises FY2024 guidance to ~$310-311M","bullets":["Revenue $81.5M, up 28% YoY; gross margin 43.3%, up ~900 bps from 34.4%.","Net loss GAAP $85.6M ($1.47/sh) includes $45M Biopharma impairment; adjusted net loss $40.6M.","Adjusted EBITDA improved to $(22.0)M from $(29.6)M YoY; orders grew to $85.3M.","FY2024 revenue guidance raised to ~$310-311M; gross margin guidance ~42% (high end).","SynBio revenue $33.0M, NGS $43.4M, Biopharma $5.1M; cash $289.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-034277","json":"https://secwatch.observer/filing/0001628280-24-034277.json","markdown":"https://secwatch.observer/filing/0001628280-24-034277.md","text":"https://secwatch.observer/filing/0001628280-24-034277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000162828024034277/0001628280-24-034277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000162828024034277/twist-20240802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:27:56.113417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}